LJPCのチャート
LJPCの企業情報
| symbol | LJPC |
|---|---|
| 会社名 | La Jolla Pharmaceutical Co. （ラホヤ・ファ―マシュ―ティカル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ラ・ホイヤ・ファーマシューティカル(La Jolla Pharmaceutical Company)はバイオ医薬品企業である。同社は生命を脅かす疾患に罹患している患者の転帰を改善するための治療法の発見、開発および商業化に従事する。LJPC-501は、カテコールアミン耐性低血圧（CRH）の潜在的治療に対するアンギオテンシンIIの製剤である。同社は高出力ショック3（ATHOS）第III相試験の治療のためのアンギオテンシンIIと呼ばれる、CRHの治療のためのLJPC-501の第III相試験を開始した。LJPC-401は、遺伝性ヘモクロマトーシス、ベータサラセミア、鎌状赤血球症および骨髄異形成症候群のような鉄過剰によって特徴付けられる状態の潜在的な治療のための合成ヒトヘプシジンの製剤である。LJPC-30Sは、嚢胞性線維症やデュシェンヌ型筋ジストロフィーなどの稀な遺伝病、深刻な細菌感染の治療用の治療法に焦点を当てた次世代のゲンタマイシン誘導体プログラムである。 ラホヤ・ファ―マシュ―ティカルは米国のバイオ医薬品企業。慢性的な臓器不全や癌の治療薬の発見、開発、商業化に焦点を当てる。慢性腎疾患を有する患者の治療薬｢GCS-100｣、レニン ・アンジオテンシン・システムのペプチド作動薬｢LJPC-501｣、溶血性貧血などの鉄過剰の障害の治療として知られるヘプシジン｢LJPC-401｣がある。 La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria. |
| 本社所在地 | 4550 Towne Centre Court San Diego CA 92121 USA |
| 代表者氏名 | Kevin C. Tang ケヴィン・C・タング |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-207-4264 |
| 設立年月日 | 32629 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1994年 |
| 従業員数 | 309人 |
| url | www.ljpc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ljpc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -164.81500 |
| 終値（lastsale） | 17.97 |
| 時価総額（marketcap） | 471284831.97 |
| 時価総額 | 時価総額（百万ドル） 423.81540 |
| 売上高 | 売上高（百万ドル） 2.40200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 189.03140 |
| 当期純利益 | 当期純利益（百万ドル） -168.14000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 La Jolla Pharmaceutical Company revenues increased from $0K to $2.4M. Net loss increased from $50M to $103.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - other increase from $6.9M to $17.9M (expense) Stock-based Compensation in R&D increase from $5M to $11.1M (expense). |
LJPCのテクニカル分析
LJPCのニュース
Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? 2022/08/17 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price is hovering lower on Tuesday, August 16, dropping -2.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $6.20, with intraday deals fluctuating between $6.19 and $6.22. The company’s 5Y monthly beta was ticking 1.97 while its P/E ratio … Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? Read More »
Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC 2022/07/16 05:14:00 PR Newswire
NEW YORK, July 16, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered…
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge 2022/07/11 18:42:13 Benzinga
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE: ENIC ), up 3% and UGI Corp (NYSE: UGI ) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE: AZZ ) reported better-than-expected earnings for its first quarter on Monday. AZZ reported first-quarter FY23 sales growth of 36.8% year-over-year to $314.4 million, beating the consensus of $268.09 million. Adjusted EPS jumped 59.1% Y/Y to $1.40, beating the consensus of $1.03. Equities Trading UP Pliant Therapeutics, Inc. (NASDAQ: PLRX ) shares shot up 125% to $20.00 after the company said its treatment for Idiopathic Pulmonary …
BLI, GNFT and AWH among mid-day movers 2022/07/11 16:52:12 Seeking Alpha
Gainers: Pliant Therapeutics PLRX +114%.Kaspien Holdings (KSPN) +99%.Iterum Therapeutics ITRM +83%.La Jolla Pharmaceutical Company LJPC +81%.Digital World Acquisition…
Why These Casino Stocks Are Moving Lower, Here''s 45 Stocks Moving In Monday''s Mid-Day Session 2022/07/11 16:11:18 Benzinga
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX ) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ: LJPC ) gained 80.9% to $6.13 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ: ITRM ) surged 71.8% to $0.4124 after the company announced that it has reached an agreement with the FDA under the special protocol assessment process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid to begin in Q4. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 39.6% to $3.63. Volcon, Inc. (NASDAQ: VLCN ) gained 32.5% to $2.1299. Volcon received thousands of non-binding pre-production orders, which, if finalized, would result in more than $70 million worth of revenue following delivery.
Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? 2022/08/17 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price is hovering lower on Tuesday, August 16, dropping -2.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $6.20, with intraday deals fluctuating between $6.19 and $6.22. The company’s 5Y monthly beta was ticking 1.97 while its P/E ratio … Are Investors Eager To Sell Holdings In La Jolla Pharmaceutical Company (NASDAQ: LJPC)? Read More »
Equity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPC 2022/07/16 05:14:00 PR Newswire
NEW YORK, July 16, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered…
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge 2022/07/11 18:42:13 Benzinga
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June. The Dow traded down 0.30% to 31,242.86 while the NASDAQ fell 1.85% to 11,419.99. The S&P also fell, dropping, 0.92% to 3,863.48. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Utilities shares rose by 0.3% on Monday. Meanwhile, top gainers in the sector included Enel Chile SA - ADR (NYSE: ENIC ), up 3% and UGI Corp (NYSE: UGI ) up 2%. In trading on Monday, communication services shares dipped by 2.6%. Top Headline AZZ Inc (NYSE: AZZ ) reported better-than-expected earnings for its first quarter on Monday. AZZ reported first-quarter FY23 sales growth of 36.8% year-over-year to $314.4 million, beating the consensus of $268.09 million. Adjusted EPS jumped 59.1% Y/Y to $1.40, beating the consensus of $1.03. Equities Trading UP Pliant Therapeutics, Inc. (NASDAQ: PLRX ) shares shot up 125% to $20.00 after the company said its treatment for Idiopathic Pulmonary …
BLI, GNFT and AWH among mid-day movers 2022/07/11 16:52:12 Seeking Alpha
Gainers: Pliant Therapeutics PLRX +114%.Kaspien Holdings (KSPN) +99%.Iterum Therapeutics ITRM +83%.La Jolla Pharmaceutical Company LJPC +81%.Digital World Acquisition…
Why These Casino Stocks Are Moving Lower, Here''s 45 Stocks Moving In Monday''s Mid-Day Session 2022/07/11 16:11:18 Benzinga
Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX ) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study. La Jolla Pharmaceutical Company (NASDAQ: LJPC ) gained 80.9% to $6.13 after Innoviva entered into a definitive agreement to acquire the company for $5.95 per share and an incremental $0.28 per share for additional cash proceeds, or an implied enterprise value of approximately $149 million. Iterum Therapeutics plc (NASDAQ: ITRM ) surged 71.8% to $0.4124 after the company announced that it has reached an agreement with the FDA under the special protocol assessment process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid to begin in Q4. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 39.6% to $3.63. Volcon, Inc. (NASDAQ: VLCN ) gained 32.5% to $2.1299. Volcon received thousands of non-binding pre-production orders, which, if finalized, would result in more than $70 million worth of revenue following delivery.
La Jolla Pharmaceutical GAAP EPS of $0.11 beats by $0.07, revenue of $12.2M misses by $1.83M 2022/03/09 14:11:06 Seeking Alpha
La Jolla Pharmaceutical press release (LJPC): Q4 GAAP EPS of $0.11 beats by $0.07.Revenue of $12.2M (+10.9% Y/Y) misses by $1.83M.Shares +5.47%.
La Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded by Zacks Investment Research to Buy 2021/12/18 09:54:42 Dakota Financial News
Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $5.00 price objective on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development []
La Jolla Pharmaceutical (NASDAQ:LJPC) Downgraded by Zacks Investment Research 2021/12/14 06:36:42 Dakota Financial News
La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “ NASDAQ:LJPC opened […]
La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic 2021/12/11 20:00:00 Stocks Register
La Jolla Pharmaceutical Company (NASDAQ:LJPC) price on Friday, December 10, rose 5.08% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.55. A look at the stocks price movement, the close in the last trading session was $4.33. The beta value (5-Year monthly) was 2.36 while the PE La Jolla Pharmaceutical Company (NASDAQ: LJPC) Rise 5.08%, Now What? Dont Panic Read More »
La Jolla Pharmaceutical (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research 2021/12/08 06:08:42 ETF Daily News
Zacks Investment Research upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a hold rating to a buy rating in a report released on Saturday, Zacks.com reports. The brokerage currently has $4.25 price target on the biopharmaceutical companys stock. According to Zacks, LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products [] The post La Jolla Pharmaceutical (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .